Figures & data
Table 1. Hexaxim composition (per 0.5 mL dose).
Figure 1. Hexaxim use in clinical practices around the world in the past decade (2013 – 2023).
Countries where Hexaxim has been used in clinical practices between June 2013 and April 2023 are shown in purple.
Depending on the country, Hexaxim may be funded/reimbursed as part of the National Immunization Program or available only as an out-of-pocket vaccine.
Figure 2. Seroprotection/Seroconversion rates 1 month after a primary vaccination with 2 or 3 doses of Hexaxim.
Figure 3. Seroprotection/Seroconversion rates 1 month after a booster vaccination of Hexaxim in the second year of life.
Table 2. Summary of Hexaxim clinical trials (primary series, booster, and antibody persistence).
Figure 4. Persistent immune memory to HB following 2, 4, 6 month primary series vaccination of Hexaxim and no booster.
Source: Kosalaraska et al (2018) [Citation36].
Table 3. Solicited reactions after any infant vaccination – integrated analysis of Hexaxim versus Infanrix hexa.
Table 4. Characteristics of AE reports and the 10 most common events reported after DTaP-IPV-HB-Hib vaccination (June 1, 2013 to April 17, 2023).
Figure 5. Evolution of the reporting rate for adverse events of special interest.
Table 5. Observed versus expected analysis for Sudden Infant Death Syndrome/Sudden Death in the European Economic Area.
Supplemental material